Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MOHAMMAD TAHIR

Allopathic & Osteopathic Physicians Internal Medicine Cardiovascular Disease

NPI
1881608008
CMS profile
312322
Location
SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$54,457.41

97 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Consulting Fee $53,212.08 24
Food and Beverage $1,245.33 73

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MOHAMMAD TAHIR

NPI 1881608008 · CMS profile ID 312322

Allopathic & Osteopathic Physicians / Internal Medicine / Cardiovascular Disease

SAINT LOUIS, MO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1881608008?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MOHAMMAD TAHIR, NPI 1881608008, CMS profile ID 312322. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881608008?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). MOHAMMAD TAHIR, NPI 1881608008, CMS profile ID 312322. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881608008?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
MOHAMMAD TAHIR, NPI 1881608008, CMS profile ID 312322, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–97 of 97 matching records. This page contains 47 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1881608008?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

97 matching records · $54,457.41 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 97 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–97 of 97.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Merck Sharp & Dohme LLC $11.0706/26/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141790212 CMS
Novo Nordisk Inc $23.7106/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1096995721 CMS
Merck Sharp & Dohme LLC $19.8506/20/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141790216 CMS
Novartis Pharmaceuticals Corporation $11.0306/12/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401160 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6706/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685360 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6706/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685362 CMS
Novartis Pharmaceuticals Corporation $3.8706/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401162 CMS
Novartis Pharmaceuticals Corporation $25.4506/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401164 CMS
Kiniksa Pharmaceuticals International, plc $21.1806/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154899983 CMS
Novartis Pharmaceuticals Corporation $18.5305/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401166 CMS
Kestra Medical Technology Services, Inc. $13.1605/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152379580 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6705/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685356 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6705/10/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685358 CMS
Kestra Medical Technology Services, Inc. $15.7905/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1152379578 CMS
Janssen Pharmaceuticals, Inc $23.7004/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078060384 CMS
Novartis Pharmaceuticals Corporation $18.6704/24/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401158 CMS
Kiniksa Pharmaceuticals International, plc $23.0004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154899937 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6704/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685352 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6704/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685354 CMS
Esperion Therapeutics, Inc. $22.3004/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129457242 CMS
Abbott Laboratories $80.9604/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1125318999 CMS
Novo Nordisk Inc $14.0703/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1097117810 CMS
Novartis Pharmaceuticals Corporation $2.3303/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401148 CMS
Novartis Pharmaceuticals Corporation $14.1303/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401150 CMS
Novartis Pharmaceuticals Corporation $1.4303/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401156 CMS
Kiniksa Pharmaceuticals International, plc $26.6703/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154899919 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6703/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685348 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6703/11/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685350 CMS
E.R. Squibb & Sons, L.L.C. $32.8403/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101586429 CMS
Kiniksa Pharmaceuticals International, plc $21.0503/04/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1154899917 CMS
Novartis Pharmaceuticals Corporation $15.3402/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401154 CMS
Amgen Inc. $17.7702/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116167692 CMS
Novartis Pharmaceuticals Corporation $0.9802/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401152 CMS
Novartis Pharmaceuticals Corporation $20.7302/15/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401146 CMS
Bayer Healthcare Pharmaceuticals Inc. $17.7502/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086112612 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6702/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685344 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6702/14/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685346 CMS
Novartis Pharmaceuticals Corporation $0.8102/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401144 CMS
Esperion Therapeutics, Inc. $17.1402/01/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1129457240 CMS
Novartis Pharmaceuticals Corporation $15.2601/31/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1087401142 CMS
Janssen Pharmaceuticals, Inc $25.9701/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078060094 CMS
Merck Sharp & Dohme LLC $23.4001/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141899458 CMS
SANOFI-AVENTIS U.S. LLC $20.6201/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1139640165 CMS
Janssen Pharmaceuticals, Inc $22.0301/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078061342 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,267.6701/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685340 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2,166.6701/17/2024 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137685342 CMS
Merck Sharp & Dohme LLC $16.3901/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1141790372 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $5,090.77 72
PY2020 $1,090.87 74
PY2021 $4,407.36 154
PY2022 $29,208.46 83
PY2023 $22,252.75 89
PY2024 $54,457.41 97
PY2025 $56,969.47 98

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $301,380.00 14
PY2024 Principal investigator $505,327.45 28
PY2023 Principal investigator $330,185.74 27
PY2022 Principal investigator $712,330.72 896
PY2021 Principal investigator $150,992.99 473
PY2020 Principal investigator $232,340.99 11
PY2019 Principal investigator $280,617.32 15

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

14 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $10,200.00 12/12/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235815
Principal investigator 1 Janssen Research & Development, LLC $17,880.00 11/19/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235764
Principal investigator 1 Janssen Research & Development, LLC $36,500.00 11/07/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235807
Principal investigator 1 Janssen Research & Development, LLC $2,860.00 11/03/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235770
Principal investigator 1 Janssen Research & Development, LLC $19,500.00 09/19/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235740
Principal investigator 1 Janssen Research & Development, LLC $17,010.00 08/25/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235682
Principal investigator 1 Janssen Research & Development, LLC $21,000.00 07/23/2025 Non-covered Recipient Entity
St Louis Heart Vascular
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235652
Principal investigator 1 Janssen Research & Development, LLC $5,830.00 06/23/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235793
Principal investigator 1 Janssen Research & Development, LLC $19,650.00 06/20/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235734
Principal investigator 1 Janssen Research & Development, LLC $24,400.00 05/21/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235660
Principal investigator 1 Janssen Research & Development, LLC $34,950.00 04/23/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235706
Principal investigator 1 Janssen Research & Development, LLC $19,750.00 03/21/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235756
Principal investigator 1 Janssen Research & Development, LLC $24,650.00 02/19/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235778
Principal investigator 1 Janssen Research & Development, LLC $47,200.00 01/22/2025 Non-covered Recipient Entity
Saint Louis Heart and Vascular, PC
A Phase 3, Randomized, Double-Blind, Double-Dummy, Parallel Group, Active Controlled Study to Evaluate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, Versus Apixaban in Participants with Atrial Fibrillation No dispute reported 06/30/2026 1175235798